about
A novel microbiota stratification system predicts future exacerbations in bronchiectasisMatrix metalloproteinases vary with airway microbiota composition and lung function in non-cystic fibrosis bronchiectasisAdult non-cystic fibrosis bronchiectasis is characterised by airway luminal Th17 pathway activation.The effect of long-term macrolide treatment on respiratory microbiota composition in non-cystic fibrosis bronchiectasis: an analysis from the randomised, double-blind, placebo-controlled BLESS trial.Culture-Independent Detection of Nontuberculous Mycobacteria in Clinical Respiratory Samples.FUT2 genotype influences lung function, exacerbation frequency and airway microbiota in non-CF bronchiectasis.Macrolide Treatment Inhibits Pseudomonas aeruginosa Quorum Sensing in Non-Cystic Fibrosis Bronchiectasis. An Analysis from the Bronchiectasis and Low-Dose Erythromycin Study Trial.Impact of Long-Term Erythromycin Therapy on the Oropharyngeal Microbiome and Resistance Gene Reservoir in Non-Cystic Fibrosis Bronchiectasis.Oxidative and endoplasmic reticulum stress in respiratory disease.Understanding the impact of antibiotic therapies on the respiratory tract resistome: a novel pooled-template metagenomic sequencing strategyOpportunistic bacteria confer the ability to ferment prebiotic starch in the adult cystic fibrosis gutVX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del AllelesPPARγ is reduced in the airways of non-CF bronchiectasis subjects and is inversely correlated with the presence of Pseudomonas aeruginosaAustralian adults with bronchiectasis: The first report from the Australian Bronchiectasis RegistryLong-term macrolide antibiotics for the treatment of bronchiectasis in adults: an individual participant data meta-analysisThe impact of CFTR modulator therapies on CF airway microbiology
P50
Q28235177-CDF1FDE4-C02A-4FF9-A126-3572B00306B3Q28256930-CF2D28C3-C5B9-4E7F-8A27-717E9F8527C1Q35231255-5BA2D90C-35AE-491D-9347-8F624BCF33CDQ35472705-6D89418F-67EB-48F6-A858-78FE79D7A48DQ37218631-87628B1D-50E3-42F3-A061-CA0BB0153B8CQ40583472-4220EC72-1AD7-4C15-9319-811C8DD1007DQ40597951-97CF3B1E-601A-4F2A-A169-6AC98AF673ECQ52579711-6F04D4AA-8835-4C2F-8BB3-E60674BD723BQ55233756-2485C4DC-9ED2-49DE-9C85-66C74CC74650Q56523707-CD20632B-1B66-4395-A336-920FE6E9CE44Q57785591-4FF6E932-4243-42C7-8867-2E14299C7725Q57788334-DDB9A5D6-84BE-4A88-A3C6-3F6CD5293A6FQ58775115-E1981431-CCFC-4B56-82B8-5DD1F4A4F12CQ92049469-DD1B5307-CDA5-42BA-92FE-E03CE141A5C1Q92575426-A862A654-30D6-474C-BB6B-9BA52109618BQ92645599-6CDB6151-1D12-45CF-9584-30C1C8FBAF19
P50
description
researcher ORCID ID = 0000-0003-4010-3787
@en
wetenschapper
@nl
name
Lucy D Burr
@ast
Lucy D Burr
@en
Lucy D Burr
@es
Lucy D Burr
@nl
type
label
Lucy D Burr
@ast
Lucy D Burr
@en
Lucy D Burr
@es
Lucy D Burr
@nl
prefLabel
Lucy D Burr
@ast
Lucy D Burr
@en
Lucy D Burr
@es
Lucy D Burr
@nl
P106
P1153
56241356800
P31
P496
0000-0003-4010-3787